Court stings AbbVie with an AndroGel fine

A US district court has ordered AbbVie and partner Besins Healthcare to repay consumers US$448 million, plus interest, for using ‘sham litigation’ to unlawfully delay generic competition to AbbVie’s AndroGel (testosterone) 1% gel brand, in the largest monetary award ever in a litigated US Federal Trade Commission (FTC) antitrust case.